AtriCure, Inc. reported a notable increase in financial performance for the first quarter of 2026, with total revenue reaching $141.2 million, a 14.3% increase from $123.6 million in the same period of 2025. The company achieved a gross profit of $109.3 million, reflecting a gross margin of 77.4%, up from 74.9% a year earlier. AtriCure's net income for the quarter was $108, compared to a net loss of $6.7 million in the prior year, marking a significant turnaround in profitability.
The company's operational metrics showed improvements across several key product lines. Revenue from the United States increased by 14.9%, driven by strong sales in appendage management and pain management products, particularly the AtriClip® FLEX-Mini and PRO-Mini devices. International sales also grew by 11.5%, with notable contributions from Europe and the Asia Pacific regions. However, sales in minimally invasive ablation declined by 24.7%, attributed to a shift in physician preference towards pulsed field ablation (PFA) catheters.
Strategically, AtriCure has focused on product innovation and clinical research to enhance its market position. The company received CE mark approval for its AtriClip FLEX-Mini and PRO-Mini devices in April 2026, with plans to launch these products in Europe later this year. Additionally, AtriCure is actively engaged in clinical trials, including the LeAAPS trial, which evaluates the effectiveness of left atrial appendage exclusion in preventing strokes, and the BoxX-NoAF trial, assessing the impact of concomitant ablation procedures.
As of March 31, 2026, AtriCure's cash and cash equivalents totaled $146.2 million, with outstanding debt of $61 million and unused borrowing capacity of $62.8 million under its asset-based revolving credit facility. The company reported a net working capital of $240.5 million and an accumulated deficit of $413.1 million. Looking ahead, AtriCure anticipates continued revenue growth driven by its product innovations and strategic initiatives, while also monitoring market conditions and competitive dynamics that may impact its performance.
About AtriCure, Inc.
AtriCure, Inc. develops and markets medical devices for the surgical treatment of atrial fibrillation (Afib), left atrial appendage management (LAAM), and post-operative pain management. Its product portfolio includes radiofrequency and cryoablation systems, the AtriClip LAA exclusion device, and cryo nerve block probes. Serving cardiothoracic surgeons and electrophysiologists globally, AtriCure’s technologies offer clinically proven, less invasive solutions to improve patient outcomes and reduce stroke risk and post-surgical pain.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.